Alle verbonden artikelen

Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Auteurs : Von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber Rd, Piccart-Gebhart M, Baselga J
Jaar : 2017
Journal : N Engl J Med
Volume : 377(2)
Pagina's : 122-131

3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3).

Auteurs : Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart-Gebhart M, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E
Jaar : 2017
Journal : Ann Oncol
Volume : 28(1)
Pagina's : 16-33

New Drug Combination Strategies in Melanoma: Current Status and Future Directions.

Auteurs : Najem A, Krayem M, Perdrix A, Kerger J, Awada A, Journe F, Ghanem G
Jaar : 2017
Journal : Anticancer Res
Volume : 37
Pagina's : 5941-5953

Abiraterone acetate post-docetaxel for metastatic castration-resistant prostate cancer in the Belgian compassionate use program.

Auteurs : Van Praet C, Rottey S, Van Hende F, Pelgrims G, Demey W, Van Aelst F, Wynendaele W, Gil T, Schatteman P, Filleul B, Schallier D, Machiels JP, Schrijvers D, Everaert E, Dhont L, Werbrouck P, Vermeij J, Mebis J, Clausse M, Rasschaert M, Van Erps J, Verheezen J, Van Haverbeke J, Goeminne JC, Lumen N
Jaar : 2016
Journal : Urol Oncol
Volume : 34(6)
Pagina's : 254.e7-254.e13

Guidance for the prevention and treatment of venous thromboembolism in cancer patients

Auteurs : Awada A, Baurain JF, Clement P, Hainaut P, Holbrechts S, Hougardy JM, Jochmans K, Mathieu V, Mebis J, Strijbos MH, Vulsteke C, Verheij M
Jaar : 2016
Journal : Belgian J Medical Oncology
Volume : 7(6)
Pagina's : 217-23

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

Auteurs : Cardoso F, Vant Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, Pierga JY, Brain E, Causeret S, Delorenzi M, Glas AM, Golfinopoulos V, Goulioti T, Knox S, Matos E, Meulemans B, Neijenhuis PA, Nitz U, Passalacqua R, Ravdin P, Rubio IT, Saghatchian M, Smilde TJ, Sotiriou C, Stork L, Straehle C, Thomas G, Thompson AM, van der Hoeven JM, Vuylsteke P, Bernards R, Tryfonidis K, Rutgers E, Piccart-Gebhart M
Jaar : 2016
Journal : N Engl J Med
Volume : 375(8)
Pagina's : 717-29

Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial.

Auteurs : Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M, van den Eerenbeemt J, Buttice A, Gombos A, de Valeriola D, Gil T, Piccart-Gebhart M, Awada A
Jaar : 2016
Journal : Eur J Cancer
Volume : 60
Pagina's : 117-124

Immune checkpoint inhibitors renal side effects and management.

Auteurs : Rassy EE, Kourie HR, Rizkallah J, Karak FE, Hanna C, Chelala DN, Ghosn M
Jaar : 2016
Journal : Immunotherapy
Volume : 8
Pagina's : 1417-1425

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

Auteurs : Strasser-Weippl K, Horick N, Smith IE, O Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE
Jaar : 2016
Journal : Eur J Cancer
Volume : 56
Pagina's : 85-92

The Future of Access to Innovative Medicines in Cancer Therapy: Towards Conditional Dialogue Fostering Affordable Therapeutic Innovation

Auteurs : van Dyk N, De Greve J, Schots R, Awada A, Van Eycken L, Geldof T
Jaar : 2016
Journal : Vlerick business school
Volume : 7
Pagina's : -

Immune checkpoint inhibitors side effects and management.

Auteurs : Kourie HR, Klastersky J
Jaar : 2016
Journal : Immunotherapy
Volume : 8
Pagina's : 799-807

Tumour-educated circulating monocytes are powerful candidate biomarkers for diagnosis and disease follow-up of colorectal cancer.

Auteurs : Hamm A, Prenen H, Van Delm W, Di Matteo M, Wenes M, Delamarre E, Schmidt T, Weitz J, Sarmiento R, Dezi A, Gasparini G, Rothé F, Schmitz R, Dhoore A, Iserentant H, Hendlisz A, Mazzone M
Jaar : 2016
Journal : Gut
Volume : 65(6)
Pagina's : 990-1000

Too little benefit for too much toxicity: rethinking the adjuvant development model in colon cancer.

Auteurs : Hendlisz A, Bleiberg H
Jaar : 2016
Journal : Curr Opin Oncol
Volume : 28(4)
Pagina's : 345-7

Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.

Auteurs : Habre M, Habre SB, Kourie HR
Jaar : 2016
Journal : Immunotherapy
Volume : 8
Pagina's : 1437-1446

Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.

Auteurs : Harbeck N, Huang CS, Hurvitz S, Yeh DC, Shao Z, Im SA, Jung KH, Shen K, Ro J, Jassem J, Zhang Q, Im YH, Wojtukiewicz M, Sun Q, Chen SC, Goeldner RG, Uttenreuther-Fischer M, Xu B, Piccart-Gebhart M
Jaar : 2016
Journal : Lancet Oncol
Volume : 17(3)
Pagina's : 357-66

Progressive multifocal leukoencephalopathy mimicking cerebral metastases in a patient treated for nasopharyngeal carcinoma

Auteurs : Oualla K, Aoun F, Lemort M, Harrouk A, Latifyan S, Awada A, Georgala A
Jaar : 2016
Journal : Belgian J Medical Oncology
Volume : 10(7)
Pagina's : 276-280

Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial.

Auteurs : Loi S, Dafni U, Karlis D, Polydoropoulou V, Young BM, Willis S, Long B, de Azambuja E, Sotiriou C, Viale G, Rüschoff J, Piccart-Gebhart M, Dowsett M, Michiels S, Leyland-Jones B
Jaar : 2016
Journal : JAMA Oncol
Volume : 2(8)
Pagina's : 1040-7

Supportive/palliative care in cancer patients: quo vadis?

Auteurs : Klastersky J, Libert I, Michel B, Obiols M, Lossignol D
Jaar : 2016
Journal : Support Care Cancer
Volume : 24(4)
Pagina's : 1883-8

Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer.

Auteurs : Twelves C, Jove M, Gombos A, Awada A
Jaar : 2016
Journal : Crit Rev Oncol Hematol
Volume : 100
Pagina's : 74-87

Understanding the risk for infection in patients with neutropenia.

Auteurs : Klastersky J, Meert AP
Jaar : 2016
Journal : Intensive Care Med
Volume : 42(2)
Pagina's : 268-70